CY1123254T1 - Μεθοδοι για μεταγωγη και επεξεργασια κυτταρων - Google Patents

Μεθοδοι για μεταγωγη και επεξεργασια κυτταρων

Info

Publication number
CY1123254T1
CY1123254T1 CY20201100763T CY201100763T CY1123254T1 CY 1123254 T1 CY1123254 T1 CY 1123254T1 CY 20201100763 T CY20201100763 T CY 20201100763T CY 201100763 T CY201100763 T CY 201100763T CY 1123254 T1 CY1123254 T1 CY 1123254T1
Authority
CY
Cyprus
Prior art keywords
methods
processing
cells
increased
chamber
Prior art date
Application number
CY20201100763T
Other languages
English (en)
Inventor
Ryan L. CRISMAN
Chris RAMSBORG
Travis WOOD
Original Assignee
Juno Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juno Therapeutics, Inc. filed Critical Juno Therapeutics, Inc.
Publication of CY1123254T1 publication Critical patent/CY1123254T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B04—CENTRIFUGAL APPARATUS OR MACHINES FOR CARRYING-OUT PHYSICAL OR CHEMICAL PROCESSES
    • B04B—CENTRIFUGES
    • B04B7/00—Elements of centrifuges
    • B04B7/08—Rotary bowls
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

Παρέχονται μέθοδοι, συστήματα και κιτ για επεξεργασία κυττάρων, π.χ., για θεραπευτική χρήση, όπως για κατ'αποδοχή κυτταρική θεραπεία. Οι παρεχόμενες μέθοδοι περιλαμβάνουν μεθόδους στις οποίες κύτταρα και ιός επωάζονται υπό συνθήκες που έχουν ως αποτέλεσμα μεταγωγή των κυττάρων με έναν ιικό φορέα. Η επώαση σε μερικές υλοποιήσεις διεξάγεται σε μία εσωτερική κοιλότητα ενός γενικά άκαμπτου φυγοκεντρικού θαλάμου, όπως ένας κυλινδρικός θάλαμος κατασκευασμένος από σκληρό πλαστικό, η κοιλότητα του οποίου μπορεί να έχει έναν κυμαινόμενο όγκο. Οι μέθοδοι περιλαμβάνουν άλλα στάδια επεξεργασίας, συμπεριλαμβανομένων αυτών που διεξάγονται σε έναν τέτοιο θάλαμο, που περιλαμβάνουν πλύσιμο, επιλογή, απομόνωση, καλλιέργεια και μορφοποίηση. Συγκεκριμένα, η αποκάλυψη σχετίζεται με μέθοδο που παρέχει πλεονεκτήματα σε σχέση με τις διαθέσιμες μεθόδους επεξεργασίας, όπως ως διαθέσιμοι μέθοδοι για επεξεργασία μεγάλης κλίμακας. Τέτοια πλεονεκτήματα συμπεριλαμβάνουν, για παράδειγμα, μειωμένο κόστος, εξορθολογισμό, αυξημένη αποτελεσματικότητα, αυξημένη ασφάλεια και αυξημένη αναπαραγωγικότητα μεταξύ διαφόρων υποκειμένων και συνθηκών.
CY20201100763T 2014-11-05 2020-08-13 Μεθοδοι για μεταγωγη και επεξεργασια κυτταρων CY1123254T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462075801P 2014-11-05 2014-11-05
US201562129023P 2015-03-05 2015-03-05
PCT/US2015/059030 WO2016073602A2 (en) 2014-11-05 2015-11-04 Methods for transduction and cell processing

Publications (1)

Publication Number Publication Date
CY1123254T1 true CY1123254T1 (el) 2021-10-29

Family

ID=54754736

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100763T CY1123254T1 (el) 2014-11-05 2020-08-13 Μεθοδοι για μεταγωγη και επεξεργασια κυτταρων

Country Status (27)

Country Link
US (3) US10428351B2 (el)
EP (2) EP3757206B1 (el)
JP (3) JP6740234B2 (el)
KR (2) KR102635942B1 (el)
CN (2) CN113736828A (el)
AU (3) AU2015343121B2 (el)
BR (2) BR122020002722B1 (el)
CA (1) CA2966538A1 (el)
CY (1) CY1123254T1 (el)
DK (1) DK3215601T3 (el)
ES (1) ES2805674T3 (el)
HR (1) HRP20201128T1 (el)
HU (1) HUE050264T2 (el)
IL (2) IL252126B (el)
LT (1) LT3215601T (el)
MA (1) MA40318A (el)
MX (3) MX2017005823A (el)
MY (1) MY186199A (el)
NZ (2) NZ769598A (el)
PH (1) PH12017500824A1 (el)
PL (1) PL3215601T3 (el)
PT (1) PT3215601T (el)
RS (1) RS60685B1 (el)
SG (2) SG10202002324SA (el)
SI (1) SI3215601T1 (el)
TW (3) TWI787903B (el)
WO (1) WO2016073602A2 (el)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2948544A4 (en) 2013-01-28 2016-08-03 St Jude Childrens Res Hospital CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES
CN106459914B (zh) 2014-05-15 2020-11-06 新加坡国立大学 经修饰的自然杀伤细胞及其用途
SG11201703203RA (en) 2014-10-20 2017-05-30 Juno Therapeutics Inc Methods and compositions for dosing in adoptive cell therapy
ES2805674T3 (es) 2014-11-05 2021-02-15 Juno Therapeutics Inc Métodos para la transducción y el procesamiento de células
EP3233148B1 (en) * 2014-12-19 2019-04-17 Biosafe S.A. Sequential processing of biological fluids
MA41346A (fr) 2015-01-12 2017-11-21 Juno Therapeutics Inc Eléments régulateurs post-transcriptionnels d'hépatite modifiée
FI3298033T4 (fi) 2015-05-18 2023-09-22 Tcr2 Therapeutics Inc Koostumuksia ja lääkinnällisiä käyttöjä fuusioproteiineja käyttävälle tcr:n uudelleenohjelmoinnille
BR112018008111A2 (pt) 2015-10-22 2018-11-06 Juno Therapeutics Gmbh métodos, kits, agentes e aparelhos para transdução
SG11201807661WA (en) * 2016-03-07 2018-10-30 Hitachi Chemical Advanced Therapeutics Solutions Llc A closed system for labelling and selecting live cells
WO2017161212A1 (en) 2016-03-16 2017-09-21 Juno Therapeutics, Inc. Methods for adaptive design of a treatment regimen and related treatments
JP7062640B2 (ja) 2016-07-29 2022-05-06 ジュノー セラピューティクス インコーポレイテッド 抗ｃｄ１９抗体に対する抗イディオタイプ抗体
CN109715668A (zh) 2016-08-02 2019-05-03 T细胞受体治疗公司 用于使用融合蛋白进行tcr重编程的组合物和方法
WO2018049420A1 (en) 2016-09-12 2018-03-15 Juno Therapeutics, Inc. Perfusion bioreactor bag assemblies
GB2564823B8 (en) 2016-10-07 2022-06-29 Tcr2 Therapeutics Inc Compositions and methods for TCR reprogramming using fusion proteins
JP7291396B2 (ja) 2016-11-22 2023-06-15 ティーシーアール２ セラピューティクス インク． 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
US20200095547A1 (en) * 2016-12-02 2020-03-26 Darya ALIZADEH Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
JP2019536461A (ja) * 2016-12-05 2019-12-19 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法のための操作細胞の産生
CN110582287A (zh) 2017-02-27 2019-12-17 朱诺治疗学股份有限公司 与在细胞疗法中给药有关的组合物、制品和方法
CN110913690A (zh) 2017-03-14 2020-03-24 朱诺治疗学股份有限公司 用于低温储存的方法
EP3600356A4 (en) 2017-03-27 2020-12-23 National University of Singapore ABBREVIATED NKG2D CHIMERIC RECEPTORS AND USES THEREOF IN IMMUNOTHERAPY WITH NATURAL KILLER CELLS
BR112019020001A2 (pt) 2017-03-27 2020-04-28 Nat Univ Singapore linhagens celulares estimuladoras para expansão ex vivo e ativação de células exterminadoras naturais
EP3427052A4 (en) * 2017-03-27 2019-12-04 Hitachi Chemical Advanced Therapeutics Solutions, LLC CLOSED SYSTEM FOR MARKING AND SELECTING LIVING CELLS
KR20200054160A (ko) * 2017-06-02 2020-05-19 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법
SG11202000606TA (en) 2017-07-29 2020-02-27 Juno Therapeutics Inc Reagents for expanding cells expressing recombinant receptors
US11447745B2 (en) * 2017-09-01 2022-09-20 Lonza Walkersville, Inc. End-to-end cell therapy automation
US20200292526A1 (en) 2017-09-07 2020-09-17 Juno Therapeutics, Inc. Methods of identifying cellular attributes related to outcomes associated with cell therapy
JP7357626B2 (ja) 2017-11-01 2023-10-06 ジュノー セラピューティクス インコーポレイテッド 操作された細胞の治療用組成物を生成するためのプロセス
MA50859A (fr) 2017-11-01 2020-09-09 Celgene Corp Procédé pour la production d'une composition de lymphocytes t
CN111556789A (zh) 2017-11-10 2020-08-18 朱诺治疗学股份有限公司 封闭系统低温器皿
US20210207080A1 (en) 2017-12-08 2021-07-08 Juno Therapeutics, Inc. Serum-free media formulation for culturing cells and methods of use thereof
SG11202005217VA (en) 2017-12-08 2020-07-29 Juno Therapeutics Inc Phenotypic markers for cell therapy and related methods
CA3084445A1 (en) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Process for producing a composition of engineered t cells
WO2019157298A1 (en) 2018-02-09 2019-08-15 Immatics US, Inc. Methods for manufacturing t cells
EA202190469A1 (ru) 2018-08-09 2021-06-28 Джуно Терапьютикс, Инк. Способы оценки интегрированных нуклеиновых кислот
MX2021001523A (es) 2018-08-09 2021-05-27 Juno Therapeutics Inc Procesos para generar células modificadas y composiciones de las mismas.
BR112021004261A2 (pt) 2018-09-11 2021-05-25 Juno Therapeutics Inc métodos para análise por espectrometria de massas de composições de células geneticamente modificadas
BR112021008133A2 (pt) 2018-10-31 2021-10-05 Juno Therapeutics Gmbh Métodos para seleção e estimulação de células e aparelhos para os mesmos
JP2022512917A (ja) 2018-11-01 2022-02-07 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞成熟抗原に特異的なキメラ抗原受容体を使用する処置方法
JP2022008735A (ja) * 2018-11-06 2022-01-14 テルモ株式会社 細胞製造システム、細胞製造方法、医療装置及び医療デバイス
SG11202104183RA (en) 2018-11-06 2021-05-28 Juno Therapeutics Inc Process for producing genetically engineered t cells
CN113271963A (zh) 2018-11-16 2021-08-17 朱诺治疗学股份有限公司 给予工程化t细胞以治疗b细胞恶性肿瘤的方法
CA3120869A1 (en) 2018-11-30 2020-06-04 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
SG11202105380RA (en) 2018-11-30 2021-06-29 Juno Therapeutics Inc Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
SG11202106053SA (en) * 2018-12-07 2021-07-29 Gracell Biotechnologies Shanghai Co Ltd Compositions and methods for immunotherapy
CN113195725A (zh) 2018-12-21 2021-07-30 隆萨沃克斯维尔股份有限公司 病毒载体的自动化生产
CA3123314A1 (en) 2018-12-21 2020-06-25 Octane Biotech Inc. Carousel for modular biologic production units
EP3914690A4 (en) 2019-02-08 2022-11-09 Lonza Walkersville, Inc. METHODS AND DEVICES FOR DETERMINING CELL CONCENTRATION IN AUTOMATED BIOREACTORS
WO2020180882A1 (en) 2019-03-05 2020-09-10 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
WO2020196412A1 (ja) * 2019-03-26 2020-10-01 テルモ株式会社 遠心部材及び洗浄方法
JP2022535380A (ja) 2019-06-07 2022-08-08 ジュノー セラピューティクス インコーポレイテッド 自動化ｔ細胞培養
JP7343881B2 (ja) * 2019-06-10 2023-09-13 アイ ピース，インコーポレイテッド 赤血球除去装置、単核球回収器、細胞培養装置、細胞培養システム、細胞培養方法、及び単核球の回収方法
CA3142361A1 (en) 2019-06-12 2020-12-17 Juno Therapeutics, Inc. Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
CN114555112A (zh) 2019-08-22 2022-05-27 朱诺治疗学股份有限公司 T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法
US20220392613A1 (en) 2019-08-30 2022-12-08 Juno Therapeutics, Inc. Machine learning methods for classifying cells
AU2020377043A1 (en) 2019-10-30 2022-06-02 Juno Therapeutics Gmbh Cell selection and/or stimulation devices and methods of use
WO2021092097A1 (en) 2019-11-05 2021-05-14 Juno Therapeutics, Inc. Methods of determining attributes of therapeutic t cell compositions
WO2021113780A1 (en) 2019-12-06 2021-06-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
WO2021113770A1 (en) 2019-12-06 2021-06-10 Juno Therapeutics, Inc. Methods related to toxicity and response associated with cell therapy for treating b cell malignancies
BR112022010627A2 (pt) 2019-12-06 2022-08-16 Juno Therapeutics Inc Anticorpos anti-idiotípicos para domínios de ligação alvejados por bcma e composições e métodos relacionados
TW202140790A (zh) * 2020-01-22 2021-11-01 愛爾蘭商佧琺藥業有限公司 病毒載體轉導細胞的方法
BR112022014501A2 (pt) 2020-01-24 2022-09-20 Juno Therapeutics Inc Métodos para dosagem e tratamento de linfoma folicular e linfoma de zona marginal em terapia celular adotiva
US20230090117A1 (en) 2020-01-28 2023-03-23 Juno Therapeutics, Inc. Methods for t cell transduction
CA3168941A1 (en) * 2020-02-06 2021-08-12 Cutiss Ag Cell isolation device and method
WO2021163389A1 (en) 2020-02-12 2021-08-19 Juno Therapeutics, Inc. Bcma-directed chimeric antigen receptor t cell compositions and methods and uses thereof
CA3169672A1 (en) 2020-02-12 2021-08-19 Juno Therapeutics, Inc. Cd19-directed chimeric antigen receptor t cell compositions and methods and uses thereof
WO2021202980A1 (en) * 2020-04-03 2021-10-07 Millennium Pharmaceuticals, Inc. Enhanced viral transduction efficiency
BR112022020333A2 (pt) 2020-04-10 2022-11-22 Juno Therapeutics Inc Métodos e usos relacionados à terapia celular projetada com um receptor de antígeno quimérico que alveja o antígeno de maturação de células b
JP2023528215A (ja) 2020-05-13 2023-07-04 ジュノー セラピューティクス インコーポレイテッド 臨床応答に関連する特徴量の特定方法およびその使用
KR20230022868A (ko) 2020-05-13 2023-02-16 주노 쎄러퓨티크스 인코퍼레이티드 재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
WO2022029660A1 (en) 2020-08-05 2022-02-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
CA3211006A1 (en) 2021-02-20 2022-08-25 Kite Pharma, Inc. Gene markers for sellecting immunotherapies
WO2022204070A1 (en) 2021-03-22 2022-09-29 Juno Therapeutics, Inc. Methods of determining potency of a therapeutic cell composition
CN117321200A (zh) 2021-03-22 2023-12-29 朱诺治疗学股份有限公司 评估病毒载体颗粒效力的方法
BR112023019847A2 (pt) 2021-03-29 2023-11-07 Juno Therapeutics Inc Métodos para dosagem e tratamento com uma combinação de uma terapia com inibidor de ponto de verificação e uma terapia com célula t car
JP2024517863A (ja) 2021-05-06 2024-04-23 ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞を刺激し、形質導入する方法
KR20230173179A (ko) 2021-05-14 2023-12-26 카이트 파마 인코포레이티드 키메라 항원 수용체 t세포 요법
WO2023159001A1 (en) 2022-02-15 2023-08-24 Kite Pharma, Inc. Predicting adverse events from immunotherapy
WO2023225569A1 (en) 2022-05-17 2023-11-23 Umoja Biopharma, Inc. Manufacturing viral particles
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
WO2023250400A1 (en) 2022-06-22 2023-12-28 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4163519A (en) 1977-11-01 1979-08-07 Union Carbide Corporation Compensating rotor
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (el) 1986-08-07 1989-12-23 Battelle Memorial Institute
SE454413B (sv) 1986-09-12 1988-05-02 Alfa Laval Separation Ab Centrifugalseparator med en rotor, vari ett bojligt organ strecker sig ett stycke lengs rotorns omkrets
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
DE68919715T2 (de) 1988-12-28 1995-04-06 Stefan Miltenyi Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
EP0557459B1 (en) 1990-11-13 1997-10-22 Immunex Corporation Bifunctional selectable fusion genes
US5911983A (en) * 1992-06-26 1999-06-15 University Of Pittsburgh Gene therapy for Gaucher disease using retroviral vectors
EP0804590A1 (en) 1993-05-21 1997-11-05 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5437998A (en) * 1993-09-09 1995-08-01 Synthecon, Inc. Gas permeable bioreactor and method of use
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1997021824A2 (en) 1995-12-15 1997-06-19 Systemix, Inc. Method for obtaining retroviral vector supernatant having high transduction efficiency
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
ATE186235T1 (de) 1996-04-24 1999-11-15 Claude Fell Zelltrennungsvorrichtung für biologische flüssigkeiten wie blut
DE69941836D1 (de) * 1998-07-10 2010-02-04 Univ Paris Curie Verfahren zur Verabreichng von Nukleinsäuren in Zellen in vitro oder ex vivo
EP1109921A4 (en) 1998-09-04 2002-08-28 Sloan Kettering Inst Cancer FOR PROSTATE-SPECIFIC MEMBRANE-ANTI-SPECIFIC FUSION RECEPTORS AND THEIR USE
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
WO2000038762A1 (en) 1998-12-24 2000-07-06 Biosafe S.A. Blood separation system particularly for concentrating hematopoietic stem cells
EP1287357A2 (en) 2000-06-02 2003-03-05 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
DE60122765D1 (de) 2000-11-07 2006-10-12 Hope City Cd19-spezifische umgezielte immunzellen
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
DE10136375A1 (de) 2001-07-26 2003-02-13 Cellgenix Technologie Transfer Verfahren zur Anreicherung von Zellen
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US7001513B2 (en) 2003-08-06 2006-02-21 Nuvue Technologies, Inc. Automated processing of a biological component
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
EP1893253B1 (en) 2005-03-23 2010-05-19 Biosafe S.A. Integrated system for collecting, processing and transplanting cell subsets, including adult stem cells, for regenerative medicine
JP5453629B2 (ja) 2006-08-23 2014-03-26 タカラバイオ株式会社 遠心用袋状容器を使用した遺伝子導入方法
HUE038506T2 (hu) 2007-03-30 2018-10-29 Memorial Sloan Kettering Cancer Center Kostimuláló ligand konstitutív expressziója adoptív módon átvitt T-limfocitákon
ES2374863T3 (es) 2007-12-07 2012-02-22 Miltenyi Biotec Gmbh Centrífuga para separar una muestra en por lo menos dos componentes.
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
SG168174A1 (en) 2008-07-16 2011-02-28 Kbi Biopharma Inc Methods and systems for manipulating particles using a fluidized bed
ES2717629T3 (es) 2009-11-03 2019-06-24 Hope City Receptor del factor de crecimiento epidérmico truncado (EGFRt) para selección de células T transducidas
KR101946441B1 (ko) 2010-03-18 2019-04-22 세스카 쎄라퓨틱스 인코포레이티드 특정 세포 군집 이외의 것을 고갈시켜 혈액 또는 골수 중의 특정 세포 군집을 정제하기 위한 시스템
SE535275C2 (sv) 2010-03-31 2012-06-12 Alfa Laval Corp Ab Centrifugalseparator och rotor
JP5793567B2 (ja) * 2010-07-15 2015-10-14 テルモ ビーシーティー、インコーポレーテッド 生体液用の遠心分離装置において回転時間を最適化するための方法
DK2649086T3 (en) 2010-12-09 2017-09-18 Univ Pennsylvania USING CHEMICAL ANTIGEN RECEPTOR-MODIFIED T-CELLS TO TREAT CANCER
CN103442768A (zh) * 2011-01-18 2013-12-11 宾夕法尼亚大学董事会 治疗癌的组合物和方法
RU2688185C2 (ru) 2011-03-23 2019-05-21 Фред Хатчинсон Кэнсер Рисерч Сентер Способ и композиции для клеточной иммунотерапии
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
EP2714886B1 (en) * 2011-05-30 2020-01-22 Atech Partners Ltd. Bioreactor system for continuous cell cultivation
CN102329776B (zh) * 2011-07-20 2013-02-27 华中农业大学 一种表达Nectin-1基因胞外区片段的PK-15细胞系及其构建方法
JP6053688B2 (ja) * 2011-10-07 2016-12-27 国立大学法人三重大学 キメラ抗原受容体
EP2776451B1 (en) 2011-11-11 2018-07-18 Fred Hutchinson Cancer Research Center Cyclin a1-targeted t-cell immunotherapy for cancer
EP2594632A1 (en) * 2011-11-18 2013-05-22 Miltenyi Biotec GmbH Method and device for cell modification
EP3594245A1 (en) 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
EP2817625A2 (en) * 2012-02-23 2014-12-31 Stage Cell Therapeutics GmbH Chromatographic isolation of cells and other complex biological materials
PL2820138T3 (pl) 2012-02-29 2021-04-06 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Retrowirusowa transdukcja z zastosowaniem poloksamerów
SG11201405185PA (en) 2012-03-13 2014-10-30 Emd Millipore Corp Use of centrifugation-aided infection to increase virus titer
NZ702108A (en) 2012-05-03 2016-09-30 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
EP2698208A1 (de) 2012-08-14 2014-02-19 Fresenius Kabi Deutschland GmbH Zentrifugenvorrichtung und Verfahren zum Betreiben einer Zentrifugenvorrichtung
WO2014031687A1 (en) 2012-08-20 2014-02-27 Jensen, Michael Method and compositions for cellular immunotherapy
CN104853766A (zh) 2012-10-02 2015-08-19 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
WO2014097442A1 (ja) 2012-12-20 2014-06-26 三菱電機株式会社 車載装置及びプログラム
TWI654206B (zh) * 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
PT2981607T (pt) * 2013-04-03 2020-11-20 Memorial Sloan Kettering Cancer Center Geração eficaz de células t direcionadas a tumores, derivadas de células estaminais pluripotentes
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
JP6685900B2 (ja) 2013-10-31 2020-04-22 フレッド ハッチンソン キャンサー リサーチ センター 改変された造血幹／前駆細胞及び非エフェクターｔ細胞、そしてそれらの用途
US11400115B2 (en) 2014-04-23 2022-08-02 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
JP6661544B2 (ja) 2014-04-24 2020-03-11 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子改変したｔ細胞の自動生成法
ES2805674T3 (es) 2014-11-05 2021-02-15 Juno Therapeutics Inc Métodos para la transducción y el procesamiento de células
MA41346A (fr) 2015-01-12 2017-11-21 Juno Therapeutics Inc Eléments régulateurs post-transcriptionnels d'hépatite modifiée

Also Published As

Publication number Publication date
HRP20201128T1 (hr) 2020-10-30
AU2015343121A1 (en) 2017-05-18
BR112017009220B1 (pt) 2022-04-12
US11802295B2 (en) 2023-10-31
JP7202332B2 (ja) 2023-01-11
JP2023024691A (ja) 2023-02-16
KR102635942B1 (ko) 2024-02-14
SI3215601T1 (sl) 2020-08-31
RS60685B1 (sr) 2020-09-30
BR112017009220A2 (pt) 2017-12-26
US10428351B2 (en) 2019-10-01
AU2015343121B2 (en) 2020-06-18
US20240011051A1 (en) 2024-01-11
PL3215601T3 (pl) 2020-11-02
WO2016073602A3 (en) 2016-06-30
TW202315948A (zh) 2023-04-16
MX2017005823A (es) 2017-08-02
WO2016073602A2 (en) 2016-05-12
SG11201703656PA (en) 2017-06-29
CN113736828A (zh) 2021-12-03
US20160122782A1 (en) 2016-05-05
CN107109438A (zh) 2017-08-29
US20190376084A1 (en) 2019-12-12
PH12017500824A1 (en) 2017-10-18
MX2021001334A (es) 2021-04-12
IL292450A (en) 2022-06-01
KR20240023204A (ko) 2024-02-20
IL252126B (en) 2022-06-01
AU2022263539A1 (en) 2023-02-23
EP3757206A1 (en) 2020-12-30
NZ769595A (en) 2023-06-30
JP2020182488A (ja) 2020-11-12
TWI787903B (zh) 2022-12-21
CA2966538A1 (en) 2016-05-12
TW201636427A (zh) 2016-10-16
SG10202002324SA (en) 2020-05-28
BR122020002722B1 (pt) 2022-06-07
EP3757206B1 (en) 2024-04-10
DK3215601T3 (da) 2020-06-15
HUE050264T2 (hu) 2020-11-30
AU2020233623A1 (en) 2020-10-08
CN107109438B (zh) 2021-09-03
TW202208633A (zh) 2022-03-01
MA40318A (fr) 2017-09-13
KR20170092567A (ko) 2017-08-11
LT3215601T (lt) 2020-08-25
NZ732130A (en) 2021-11-26
ES2805674T3 (es) 2021-02-15
NZ769598A (en) 2023-05-26
EP3215601A2 (en) 2017-09-13
JP6740234B2 (ja) 2020-08-12
MY186199A (en) 2021-06-30
AU2020233623B2 (en) 2022-08-04
TWI735418B (zh) 2021-08-11
IL252126A0 (en) 2017-07-31
MX2022000159A (es) 2022-02-21
JP2017535282A (ja) 2017-11-30
PT3215601T (pt) 2020-08-03
EP3215601B1 (en) 2020-05-27

Similar Documents

Publication Publication Date Title
CY1123254T1 (el) Μεθοδοι για μεταγωγη και επεξεργασια κυτταρων
GB2573664A (en) Viral methods of T cell therapy
BR112017014551A2 (pt) ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit?
BR112019010565A2 (pt) aplicação viral de neoantígenos
MX2021000435A (es) Moleculas biespecificas que son inmunorreactivas con celulas efectoras inmunes que expresan un receptor activador y un antigeno expresado por una celula infectada por un virus y usos de las mismas.
CL2017000528A1 (es) Descubrimiento y producción de proteínas biológicas condicionalmente activas en las mismas células hospederas eucariotas de producción
EA201792441A2 (ru) Домены фибронектина типа iii, связывающиеся с простатспецифическим мембранным антигеном
BR112016020287A2 (pt) células resistentes a vírus e usos das mesmas
BR112016016916A2 (pt) método de tratamento de angiodema hereditário (hae)
SG10201902811TA (en) High efficiency, high throughput generation of genetically modified mammals by electroporation
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
MX2022000893A (es) Metodo de obtencion de mitocondrias de celulas y mitocondrias obtenidas.
WO2016073595A8 (en) T cells and dendritic cells for polyomavirus therapy
ZA202206809B (en) Hiv vaccines comprising one or more population episensus antigens
WO2018067582A3 (en) Hiv-1 env fusion peptide immunogens and their use
EA201792538A1 (ru) Способ биологического получения метакриловой кислоты
RU2016145258A (ru) Микроорганизм, обладающий улучшенным уровнем внутриклеточной энергии, и способ продуцирования l-аминокислоты с его помощью
CL2017001522A1 (es) Supresion parental rnai del gen kruppel para el control de plagas de coleopteros
EA201891335A1 (ru) Добавление аргинина с целью повышения эффективности ацетогенов, ферментирующих газ
BR112016028185A2 (pt) método para produzir um l-aminoácido.
WO2019028422A9 (en) METHODS OF ACTIVATION OF IMMUNE CELLS
EA201400634A1 (ru) Способ получения новых антибиотиков и основанная на нём рамочная система
WO2014172661A8 (en) Lone star virus
CL2017001523A1 (es) Supresion parental rnai del gen hunchback para el control de plagas de coleopteros
RU2013131721A (ru) Способ прогнозирования нейросифилиса